title: Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis.
abstract: OBJECTIVE
  Low-dose interferon alfa (IFNalpha) has been shown to have limited effects in the adjuvant treatment of patients with intermediate- and high-risk primary melanoma. We hypothesized that a combination regimen with low-dose interleukin-2 (IL-2) may improve survival prospects in these patients.
  
  
  METHODS
  After wide excision of primary melanoma without clinically detectable lymph node metastasis (pT3 to 4, cN0, M0), 225 patients from 10 participating centers were randomly assigned to receive either subcutaneous low-dose IFNalpha2b (3 million international units [MU]/m2/d, days 1 to 7, week 1; three times weekly, weeks 3 to 6, repeated all 6 weeks) plus IL-2 (9 MU/m2/d, days 1 to 4, week 2 of each cycle) for 48 weeks, or observation alone. The primary end point was prolongation of a relapse-free interval.
  
  
  RESULTS
  Of the 225 enrolled patients, 223 were found to be eligible. Median follow-up time was 79 months. All evaluated prognostic factors were well balanced between the two arms of the study. Relapses were noticed in 36 of 113 patients treated with IFNalpha2b plus IL-2 and in 34 of 110 patients with observation alone. Five-year disease-free survival of those who had routine surgery supplemented by IFNalpha2b and IL-2 treatment was 70.1% (95% confidence interval [CI], 61.3% to 78.9%), compared with 69.9% in those receiving surgery and observation alone (95% CI, 60.7% to 79.1%) in the intention-to-treat analysis. Evaluation of the overall survival did not show any difference between treated and untreated melanoma patients (P =.93).
  
  
  CONCLUSIONS
  Adjuvant treatment of intermediate- and high-risk melanoma patients with low-dose IFNalpha2b and IL-2 is safe and well tolerated by most patients, but it does not improve disease-free or overall survival.
authors.affiliation: Department of Dermatology, University of Kiel, St Georg Hospital,Hamburg, Germany. ahauschild@dermatology.uni-kiel.de.
authors.forename: Axel
authors.initials: A
authors.lastname: Hauschild
authors.forename: Michael
authors.initials: M
authors.lastname: Weichenthal
authors.forename: Bernd-Rudiger
authors.initials: BR
authors.lastname: Balda
authors.forename: Jurgen C
authors.initials: JC
authors.lastname: Becker
authors.forename: Helmut H
authors.initials: HH
authors.lastname: Wolff
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Tilgen
authors.forename: Klaus-Werner
authors.initials: KW
authors.lastname: Schulte
authors.forename: Johannes
authors.initials: J
authors.lastname: Ring
authors.forename: Dirk
authors.initials: D
authors.lastname: Schadendorf
authors.forename: Stephan
authors.initials: S
authors.lastname: Lischner
authors.forename: Gunter
authors.initials: G
authors.lastname: Burg
authors.forename: Reinhard
authors.initials: R
authors.lastname: Dummer
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000009:adverse effects / Q000627:therapeutic use*; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007376:Interleukin-2; D011994:Recombinant Proteins